Introduction: Long-term management of type 2 diabetes (T2D) and sustaining glycemic control remains a challenge and crucial for reducing clinical complications and subsequent economic costs. This study followed glycemic outcomes, average blood glucose (BG avg) and high readings ratio, over 3 years in persons using a digital therapeutic platform.
Objective: To investigate blood glucose (BG) levels in persons with T2D in high-risk who used a digital therapeutic platform to manage their BG levels over three years. Additionally, to compare outcomes between consistently engaged users over 3 years versus less consistent population.
Method: A retrospective data analysis was performed on users with T2D in high-risk (baseline BG avg>169 mg/dL in month1; equivalent to A1C 7.5) who activated between 2017-2020 and measured their BG using Dario platform over 3 consecutive years (months 1,6,12,24 and 36). The ratios assessed were BG avg and high BG readings ratio (>180 mg/dL). Digital engagement was assessed by additional parameters including measurement type (fasting/premeal/post meal/bedtime), carbs intake, meal type, and physical activity alongside glucose measurement.
Results: A group of 1,239 users significantly reduced their BG avg consistently over 3 years by 15.6% (179±55 vs. 212±42) (p<0.05) and high readings ratio by 39% (p<0.05). A subset of users completed at least one engagement type following months 12, 24, and 36 (N=433) demonstrated significantly greater reductions versus the complementary group (N=806): BG avg by 18.8% (172±51 vs. 212±45) and high readings ratio by 45% (p<0.05).
Conclusion: A digital diabetes platform has the potential to affect and sustain glycemic control improvements over 3 years. Moreover, it appears highly likely that engagement to app features in chronic condition management may help users with T2D consistently pay attention to their life behaviors to maintain better clinical outcomes.
Y.Hershcovitz: Employee; DarioHealth Corp. N.Yaniv: Employee; DarioHealth Corp. S.Budman: Employee; DarioHealth Corp. O.Manejwala: Employee; DarioHealth Corp., Stock/Shareholder; DarioHealth Corp.